Daniel Costello

Daniel Costello is a Consultant Neurologist with a subspecialty interest in Epilepsy at Cork University Hospital, and also a Senior Lecturer in Neurology at University College Cork.

His clinical duties include General Neurology, Complex Epilepsy and Rapid Access Seizure Clinic, and he has outreach Epilepsy Clinics in the community for persons with intellectual disabilities in residential care. He is the Regional (HSE-South) Clinical Lead of the National Epilepsy Clinical Care Programme and President of the Irish Chapter of the International League Against Epilepsy (ILAE) (2017-2021).

Daniel's research interests: Epilepsy and Clinical Neurophysiology with a particular interest in clinical epileptology and in the technical, interpretive and clinical aspects of EEG. He is presently involved in the following active clinical research projects:

• EP0092 Phase 3 Study of Padsevonil as add-on therapy for refractory focal epilepsy.
• Epidemiological study on the incidence of unprovoked seizures, new-onset epilepsy, provoked seizures and seizure mimics in Cork city & county
• Genetics of Epilepsy, particularly in the setting of intellectual disability
• Natural history of Mesial Temporal Lobe Epilepsy, particularly Bitemporal epilepsy
• Intractable MRI-negative focal epilepsy
• Wireless EEG technologies
• NORSE syndrome (New-Onset Refractory Status Epilepticus)

Previous studies include:

• Phase II randomized, placebo-controlled, double-blind study of minocycline in the treatment of HIV-associated cognitive impairment; MGH.
• Phase II trial of surface neurostimulation (‘Neuropace’ device) for intractable partial epilepsy in adults; MGH.
• Multicenter randomised clinical trial for the treatment of Refractory Status Epilepticus; MGH.
• VOTE study [EP0076] 2017-8. Patient preference in epilepsy monotherapy- a non-interventional study of lacosamide and other anti-epileptic drugs in the treatment of partial-onset seizures, including a discrete choice experiment.
• Phase IV study. BASE study [EP0075] 2018-9. Brivaracetam and seizure reduction in Epilepsy- a 12-month non-interventional, post-marketing multicentre study to evaluate the effectiveness of Brivaracetam as adjunctive therapy in patients with epilepsy with partial-onset seizures in daily clinical practice.